Developments in Viral Vector-Based Vaccines
Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been de...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2014-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-393X/2/3/624 |
| _version_ | 1798037987525656576 |
|---|---|
| author | Takehiro Ura Kenji Okuda Masaru Shimada |
| author_facet | Takehiro Ura Kenji Okuda Masaru Shimada |
| author_sort | Takehiro Ura |
| collection | DOAJ |
| description | Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use. |
| first_indexed | 2024-04-11T21:34:04Z |
| format | Article |
| id | doaj.art-914cc6cedbd047159fc78aadb00323c7 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-04-11T21:34:04Z |
| publishDate | 2014-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-914cc6cedbd047159fc78aadb00323c72022-12-22T04:01:48ZengMDPI AGVaccines2076-393X2014-07-012362464110.3390/vaccines2030624vaccines2030624Developments in Viral Vector-Based VaccinesTakehiro Ura0Kenji Okuda1Masaru Shimada2Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, JapanDepartment of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, JapanDepartment of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, JapanViral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.http://www.mdpi.com/2076-393X/2/3/624viral vectorvaccineCTLMVAadenovirus |
| spellingShingle | Takehiro Ura Kenji Okuda Masaru Shimada Developments in Viral Vector-Based Vaccines Vaccines viral vector vaccine CTL MVA adenovirus |
| title | Developments in Viral Vector-Based Vaccines |
| title_full | Developments in Viral Vector-Based Vaccines |
| title_fullStr | Developments in Viral Vector-Based Vaccines |
| title_full_unstemmed | Developments in Viral Vector-Based Vaccines |
| title_short | Developments in Viral Vector-Based Vaccines |
| title_sort | developments in viral vector based vaccines |
| topic | viral vector vaccine CTL MVA adenovirus |
| url | http://www.mdpi.com/2076-393X/2/3/624 |
| work_keys_str_mv | AT takehiroura developmentsinviralvectorbasedvaccines AT kenjiokuda developmentsinviralvectorbasedvaccines AT masarushimada developmentsinviralvectorbasedvaccines |